Shares of Hologic, Inc. (NASDAQ:HOLX) reached a new 52-week high during trading on Tuesday . The stock traded as high as $56.28 and last traded at $56.23, with a volume of 68518 shares. The stock had previously closed at $53.33.
Several research analysts recently commented on HOLX shares. Raymond James raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $62.00 price target on the stock in a research note on Wednesday, June 3rd. Cowen raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $64.00 price target on the stock in a research note on Tuesday. Stifel Nicolaus reduced their price target on shares of Hologic from $52.00 to $45.00 and set a “hold” rating on the stock in a research note on Wednesday, April 8th. JPMorgan Chase & Co. increased their target price on shares of Hologic from $45.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a report on Wednesday, June 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $56.83.
The firm has a market capitalization of $13.82 billion, a P/E ratio of 24.55, a PEG ratio of 3.28 and a beta of 1.44. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.04 and a current ratio of 1.31. The business’s fifty day moving average price is $52.69 and its two-hundred day moving average price is $48.88.
In related news, General Counsel John M. Griffin sold 4,906 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $50.00, for a total value of $245,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 190,996 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $50.97, for a total transaction of $9,735,066.12. The disclosure for this sale can be found here. Insiders sold a total of 238,345 shares of company stock valued at $12,185,194 over the last ninety days. 1.00% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the stock. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the 4th quarter valued at approximately $6,526,000. Ancora Advisors LLC purchased a new position in Hologic during the 4th quarter worth approximately $39,000. Signaturefd LLC raised its position in Hologic by 67.4% during the 1st quarter. Signaturefd LLC now owns 792 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 319 shares during the last quarter. Total Clarity Wealth Management Inc. purchased a new position in Hologic during the 4th quarter worth approximately $45,000. Finally, CWM LLC raised its position in Hologic by 63.4% during the 1st quarter. CWM LLC now owns 910 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 353 shares during the last quarter. 92.45% of the stock is owned by hedge funds and other institutional investors.
Hologic Company Profile (NASDAQ:HOLX)
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Read More: Quick Ratio
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.